GIM
ADMA icon

Glenmede Investment Management’s ADMA Biologics ADMA Stock Holding History

Glenmede Investment Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,737
Closed -$68K – 1420
2025
Q2 		$68K Buy
+3,737
New +$76.2K ﹤0.01% 1344

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Glenmede Investment Management's ADMA Position: Q3 2025 in Review

Glenmede Investment Management sold out of ADMA Biologics (ADMA) in Q3 2025, closing a stake of 3,737 shares — an estimated $68K sold.

Glenmede Investment Management first reported a position in ADMA in Q2 2025 and held it in 1 quarter. The position peaked at $68K in Q2 2025. 365 funds tracked by Wall St. Rank hold ADMA as of Q3 2025.

  • Glenmede Investment Management reported no remaining ADMA Biologics position as of Q3 2025 after selling out during the quarter.
  • Glenmede Investment Management sold 3,737 ADMA Biologics shares in Q3 2025, an estimated $68K.
  • Glenmede Investment Management first reported a position in ADMA Biologics in Q2 2025 and held it in 1 quarter.
  • Glenmede Investment Management's ADMA Biologics position peaked at $68K in Q2 2025.
  • 365 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.